Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes
Autore:
Schmaldienst, S; Traunmuller, F; Burgmann, H; Rosenkranz, AR; Thalhammer-Scherrer, R; Horl, WH; Thalhammer, F;
Indirizzi:
Univ Vienna, Div Infect Dis, Dept Internal Med 1, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 Internal Med 1, A-1090 Vienna, Austria Univ Vienna, Div Nephrol & Dialysis, Dept Internal Med 3, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 Internal Med 3, A-1090 Vienna, Austria Univ Vienna, Dept Lab Med, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 , Dept Lab Med, A-1090 Vienna, Austria
Titolo Testata:
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
fascicolo: 1, volume: 56, anno: 2000,
pagine: 61 - 64
SICI:
0031-6970(200004)56:1<61:MPOCIL>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
CRITICALLY ILL PATIENTS; CONTINUOUS-INFUSION; CEFTAZIDIME; INFECTIONS; BMY-28142;
Keywords:
cefepime; hemodialysis; pharmacokinetics; pharmacodynamic;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Thalhammer, F Univ Vienna, Div Infect Dis, Dept Internal Med 1, WaehringerGuertel 18-20, A-1090 Vienna, Austria Univ Vienna Waehringer Guertel 18-20Vienna Austria A-1090
Citazione:
S. Schmaldienst et al., "Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes", EUR J CL PH, 56(1), 2000, pp. 61-64

Abstract

Objective: Among uremic patients on hemodialysis, infectious complicationsleading to a high incidence of morbidity and mortality are a well-documented problem. In this multi-dose study, the safety, tolerance, and pharmacokinetics of cefepime during high-flux hemodialysis were investigated and an improved dosing schedule is presented. Methods: Six long-term hemodialysis patients received 2 g cefepime i.v. atthe end of hemodialysis three times per week. Results: Trough levels of cefepime were 23.3 +/- 7.3 mg/l and peak serum concentrations 165.6 +/- 48.7 mg/l. After 3.5 h of high-flux hemodialysis, 72.2 +/- 6.4% of cefepime was eliminated. The intradialytic half-life was 1.6 +/- 0.29 h and the interdialytic half-life 22.0 +/- 2.14 h. Conclusion: A dosage of 2 g cefepime after each hemodialysis session achieved drug levels well above the minimal inhibitory concentration (MIC)(90) for most of the target pathogens. Thus, the described dosing schedule is an efficient and cost saving antmicrobial therapy for severe infections in long-term hemodialysis patients with no residual renal function.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:30:52